Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 37 out of 100. Getting a diagnosis

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

This editorial pushes back against the 2024 revised Alzheimer's diagnostic criteria, arguing it is premature to label people as having Alzheimer's disease based on biomarkers alone when they have no symptoms and may never develop dementia. The authors warn this could cause unnecessary anxiety, over-labeling, and commercial exploitation without any proven benefit for asymptomatic people.

What this study adds

Evidence grade: Not rated

Anti-amyloid drugs that clear amyloid plaques do not consistently stop cognitive decline, suggesting that amyloid alone is not a reliable target for treating or preventing Alzheimer's disease. Its stated limit: This is an editorial/commentary, not original research; it has no participants, effect size, or study design of its own.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Zhou, R. Z., Wimo, A., & Winblad, B. (2024). Editorial: On the 2024 Alzheimer's Association Criteria: Still Not Ready for Clinical Use. The Journal of Prevention of Alzheimer's Disease.

Vancouver

Zhou RZ, Wimo A, Winblad B. Editorial: On the 2024 Alzheimer's Association Criteria: Still Not Ready for Clinical Use. The Journal of Prevention of Alzheimer's Disease. 2024.

BibTeX

@article{zhou2024-33dd7a84,
  author  = {Zhou, Robin Ziyue and Wimo, Anders and Winblad, Bengt},
  title   = {{Editorial: On the 2024 Alzheimer's Association Criteria: Still Not Ready for Clinical Use}},
  journal = {The Journal of Prevention of Alzheimer's Disease},
  year    = {2024}
}

Built from the record alzhub holds for this paper, not looked up. This record has no DOI, so the citation leaves it out. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

Anti-amyloid drugs that clear amyloid plaques do not consistently stop cognitive decline, suggesting that amyloid alone is not a reliable target for treating or preventing Alzheimer's disease. Diagnosing Alzheimer's disease in asymptomatic people based solely on biomarkers lacks evidence of benefit and risks causing unnecessary anxiety for people who may never develop dementia.

Limitations

This is an editorial/commentary, not original research; it has no participants, effect size, or study design of its own.

How this study scored 37/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record left out, no data; Study design 0 of 12; Strength of evidence left out, no data; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited left out, no data; Citations per year left out, no data; Impact for its field and year left out, no data; Cited by studies here 0 of 6; Still being cited left out, no data; Senior author's track record left out, no data; Institution's track record left out, no data; Multicenter collaboration left out, no data; Indexed in PubMed 0 of 2; Free to read left out, no data. 21 of the 57 points it could be judged on, which is 37 of 100. Total 37 of 100.21 of the 57 points we could judge = 37 of 100

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people, randomized / blinded and indexed in PubMed because the record does not state it. We have no data on strength of evidence, journal's citation record, times cited, citations per year, impact for its field and year, still being cited, senior author's track record, institution's track record, multicenter collaboration and free to read, so those were left out: it earned 21 of the 57 points we could judge it on, which is 37 out of 100.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (The Journal of Prevention of Alzheimer's Disease)
Journal's citation record — / 4 No journal record from OpenAlex — left out of this score
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence — / 5 No evidence rating recorded — left out of this score
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2024 — within 3 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited — / 7 No citation count (not found in OpenAlex) — left out of this score
Citations per year — / 5 No citation count or no year — left out of this score
Impact for its field and year — / 6 No field-weighted citation impact (OpenAlex has none yet) — left out of this score
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited — / 4 No yearly citation counts — left out of this score
Senior author's track record — / 4 Senior author's record not available — left out of this score
Institution's track record — / 3 No institution listed in OpenAlex — left out of this score
Multicenter collaboration — / 3 Institutions not listed — left out of this score
Indexed in PubMed 0 / 2 No PubMed ID and no DOI — scores zero (not stated in the record — scored 0)
Free to read — / 2 Access not recorded — left out of this score
Points 21 / 57 Scored on 10 of 20 parts. We have no data for the rest, so they are left out: 21 of the 57 points we could judge it on is 37 out of 100.
Total 37 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.

Studies in the library that share something with this one. The line above each title says what.

Related studies in Getting a diagnosis from nearby years

Also in Getting a diagnosis

141 studies in the library are filed under Getting a diagnosis with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Getting a diagnosis hub.

Similar studies

More on Getting a diagnosis

See all studies in Getting a diagnosis →